within Pharmacolibrary.Drugs.ATC.C;

model C02DB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.00015833333333333332,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0028,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02DB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hydralazine is a vasodilator used primarily to treat hypertension and congestive heart failure. It acts by directly relaxing vascular smooth muscle, leading to decreased peripheral resistance. Hydralazine is still approved and used clinically, often as adjunct therapy or when first-line antihypertensive agents are unsuitable.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from studies in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Hanson, A, et al., &amp; Wåhlander, LA (1983). Pharmacokinetics of oral hydralazine in chronic heart failure. <i>European journal of clinical pharmacology</i> 25(4) 467–473. DOI:<a href=\"https://doi.org/10.1007/BF00542113\">10.1007/BF00542113</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6653641/\">https://pubmed.ncbi.nlm.nih.gov/6653641</a></p></li><li><p>Han, LW, et al., &amp; Hebert, MF (2019). Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy. <i>Journal of clinical pharmacology</i> 59(12) 1678–1689. DOI:<a href=\"https://doi.org/10.1002/jcph.1477\">10.1002/jcph.1477</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31257615/\">https://pubmed.ncbi.nlm.nih.gov/31257615</a></p></li><li><p>Shepherd, AM, et al., &amp; Lin, MS (1980). Hydralazine kinetics after single and repeated oral doses. <i>Clinical pharmacology and therapeutics</i> 28(6) 804–811. DOI:<a href=\"https://doi.org/10.1038/clpt.1980.238\">10.1038/clpt.1980.238</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7438695/\">https://pubmed.ncbi.nlm.nih.gov/7438695</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02DB02;
